Genprex (DE:2DE)

NASDAQ:2DE

2DE

Genprex

RESEARCH TOOLSreports

Genprex (2DE) Price & Analysis

Q: What was Genprex’s price range in the past 12 months?

Genprex lowest stock price was €0.18 and its highest was €7.09 in the past 12 months.

Q: What is Genprex’s market cap?

Genprex’s market cap is €5.86M.

Q: When is Genprex’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Genprex overvalued?

According to Wall Street analysts Genprex’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Genprex pay dividends?

Genprex does not currently pay dividends.

Q: What is Genprex’s EPS estimate?

Genprex’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Genprex have?

Genprex has 10,586,402 shares outstanding.

Q: Which hedge fund is a major shareholder of Genprex?

Currently, no hedge funds are holding shares in DE:2DE

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

― Followers

2DE Stock Chart & Stats

€0.18

€0.00(0.00%)

Jun 12, 2026

―

Day’s Range― - ―

52-Week Range€0.18 - €7.10

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

€5.86M

Enterprise Value-€16.78M

Total Cash (Recent Filing)€18.05M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.00

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-15.29

Shares Outstanding10,586,402

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.21

Price to Sales (P/S)0.00

P/FCF Ratio-0.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-49.01

Revenue Forecast (FY)N/A

Genprex News

Genprex files $250M mixed securities shelf

17:03 EDT Genprex (GNPX) files $250M mixed securities shelf Published first on TheFly – the ultimate source for...

9d ago

GNPX

Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps

Genprex ( ($GNPX) ) has issued an update. On June 10, 2026, Genprex received a Nasdaq notice that...

2d ago

GNPX

Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy

Genprex ( ($GNPX) ) has shared an announcement. On May 26, 2026, Genprex announced that an abstract supported...

20d ago

GNPX

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

Genprex’s (GNPX) research collaborators presented positive preclinical data on the company’s diabetes gene therapy drug candidate at the...

1M ago

GNPX

Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy

An update from Genprex ( ($GNPX) ) is now available. On May 14, 2026, Genprex reported that its...

1M ago

GNPX

Genprex receives patent grant from The Israel Patent Office

Genprex (GNPX) announced that The Israel Patent Office has granted Genprex a patent covering the use of Reqorsa...

2M ago

GNPX

Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel

Genprex ( ($GNPX) ) has provided an announcement. On April 30, 2026, Genprex announced that the Israel Patent...

2M ago

GNPX

Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy

Genprex ( ($GNPX) ) has shared an update. On April 28, 2026, Genprex announced that research collaborators will...

2M ago

GNPX

Genprex Expands Lung Cancer Gene Therapy Research Collaboration

An announcement from Genprex ( ($GNPX) ) is now available. On April 21, 2026, Genprex announced a new...

2M ago

GNPX

Genprex enters research agreement with UT MD Anderson

Genprex (GNPX) announced the company has entered into a new Sponsored Research Agreement with The University of Texas...

2M ago

GNPX

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Genprex (GNPX) announced that its research collaborators presented at the 2026 American Association for Cancer Research, or AACR,...

2M ago

GNPX

Genprex Highlights New Reqorsa Preclinical Data at AACR

Genprex ( ($GNPX) ) has issued an announcement. On March 18, 2026, Genprex announced that its collaborators will...

3M ago

GNPX

Genprex collaborators present on use of Reqorsa at AACR meeting

Genprex (GNPX) announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research,...

3M ago

GNPX

Genprex Secures Key Global Patents for REQORSA Therapy

Genprex ( ($GNPX) ) just unveiled an update. On February 23, 2026, Genprex announced that the Japanese Patent...

4M ago

GNPX

2DE FAQ

What was Genprex’s price range in the past 12 months?

Genprex lowest stock price was €0.18 and its highest was €7.09 in the past 12 months.

What is Genprex’s market cap?

Genprex’s market cap is €5.86M.

When is Genprex’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Genprex’s earnings last quarter?

Currently, no data Available

Is Genprex overvalued?

According to Wall Street analysts Genprex’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genprex pay dividends?

Genprex does not currently pay dividends.

What is Genprex’s EPS estimate?

Genprex’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genprex have?

Genprex has 10,586,402 shares outstanding.

What happened to Genprex’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Genprex?

Currently, no hedge funds are holding shares in DE:2DE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genprex

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.